转移性骨肉瘤治疗靶点的分子改变：文献复习。
Molecular alterations as target for therapy in metastatic osteosarcoma: a review of literature.
机构信息
Department of Orthopaedic Surgery, VU University Medical Center, De Boelelaan 1117, 1081 HV, Amsterdam, The Netherlands.
出版信息
Clin Exp Metastasis. 2011 Jun;28(5):493-503. doi: 10.1007/s10585-011-9384-x. Epub 2011 Apr 2.
Abstract
Treating metastatic osteosarcoma (OS) remains a challenge in oncology. Current treatment strategies target the primary tumour rather than metastases and have a limited efficacy in the treatment of metastatic disease. Metastatic cells have specific features that render them less sensitive to therapy and targeting these features might enhance the efficacy of current treatment. A detailed study of the biological characteristics and behaviour of metastatic OS cells may provide a rational basis for innovative treatment strategies. The aim of this review is to give an overview of the biological changes in metastatic OS cells and the preclinical and clinical efforts targeting the different steps in OS metastases and how these contribute to designing a metastasis directed treatment for OS.
摘要
治疗转移性骨肉瘤（OS）仍然是肿瘤学的一个挑战。目前的治疗策略针对的是原发肿瘤，而不是转移灶，并且在转移性疾病的治疗中疗效有限。转移性细胞具有使其对治疗的敏感性降低的特定特征，针对这些特征可能会提高当前治疗的疗效。对转移性 OS 细胞的生物学特征和行为进行详细研究，可为创新治疗策略提供合理依据。本文综述的目的在于概述转移性 OS 细胞的生物学变化，以及针对 OS 转移不同步骤的临床前和临床努力，以及这些努力如何有助于设计针对 OS 的转移性治疗。
相似文献
1
Molecular alterations as target for therapy in metastatic osteosarcoma: a review of literature.
Clin Exp Metastasis. 2011 Jun;28(5):493-503. doi: 10.1007/s10585-011-9384-x. Epub 2011 Apr 2.
2
The HDAC inhibitor Vorinostat diminishes the in vitro metastatic behavior of Osteosarcoma cells.
Biomed Res Int. 2015;2015:290368. doi: 10.1155/2015/290368. Epub 2015 Feb 17.
3
Review of the molecular pathogenesis of osteosarcoma.
Asian Pac J Cancer Prev. 2014;15(15):5967-76. doi: 10.7314/apjcp.2014.15.15.5967.
4
Role of TKI for Metastatic Osteogenic Sarcoma.
Curr Treat Options Oncol. 2020 Jun 29;21(8):65. doi: 10.1007/s11864-020-00760-w.
5
Present Advances and Future Perspectives of Molecular Targeted Therapy for Osteosarcoma.
Int J Mol Sci. 2016 Apr 6;17(4):506. doi: 10.3390/ijms17040506.
6
Metastatic osteosarcoma: a curable advanced malignancy.
J Clin Oncol. 2004 Dec 15;22(24):5017; author reply 5017-8. doi: 10.1200/JCO.2004.04.234.
7
Neoadjuvant chemotherapy for osteosarcoma of the extremities with synchronous lung metastases: treatment with cisplatin, adriamycin and high dose of methotrexate and ifosfamide.
Oncol Rep. 2000 Mar-Apr;7(2):339-46. doi: 10.3892/or.7.2.339.
8
The Fas/FasL Signaling Pathway: Its Role in the Metastatic Process and as a Target for Treating Osteosarcoma Lung Metastases.
Adv Exp Med Biol. 2020;1258:177-187. doi: 10.1007/978-3-030-43085-6_12.
9
IL-6 and CXCL8 mediate osteosarcoma-lung interactions critical to metastasis.
JCI Insight. 2018 Aug 23;3(16). doi: 10.1172/jci.insight.99791.
10
Is CDK9 a promising target for both primary and metastatic osteosarcoma?
EBioMedicine. 2019 Feb;40:27-28. doi: 10.1016/j.ebiom.2019.01.016. Epub 2019 Jan 14.
引用本文的文献
1
Whole‑exome evolutionary profiling of osteosarcoma uncovers metastasis‑related driver mutations and generates an independently validated predictive classifier.
J Transl Med. 2025 Jul 7;23(1):746. doi: 10.1186/s12967-025-06796-6.
2
Sulforaphane's Role in Osteosarcoma Treatment: A Systematic Review and Meta-Analysis of Preclinical Studies.
Biomedicines. 2025 Apr 25;13(5):1048. doi: 10.3390/biomedicines13051048.
3
Whole-Exome Analysis and Osteosarcoma: A Game Still Open.
Int J Mol Sci. 2024 Dec 20;25(24):13657. doi: 10.3390/ijms252413657.
4
Employing splice-switching oligonucleotides and AAVrh74.U7 snRNA to target insulin receptor splicing and cancer hallmarks in osteosarcoma.
Mol Ther Oncol. 2024 Nov 23;32(4):200908. doi: 10.1016/j.omton.2024.200908. eCollection 2024 Dec 19.
5
Successful treatment of osteosarcoma in a pregnant woman with survival of the gestational product: A case report and literature review.
Med Int (Lond). 2024 Oct 9;4(6):73. doi: 10.3892/mi.2024.197. eCollection 2024 Nov-Dec.
6
Comprehensive analysis of splicing factor SRs-related gene characteristics: predicting osteosarcoma prognosis and immune regulation status.
Front Oncol. 2024 Sep 2;14:1456986. doi: 10.3389/fonc.2024.1456986. eCollection 2024.
7
The Landscape of microRNAs in Bone Tumor: A Comprehensive Review in Recent Studies.
Microrna. 2024;13(3):175-201. doi: 10.2174/0122115366298799240625115843.
8
A bibliometric analysis based on hotspots and frontier trends of positron emission tomography/computed tomography utility in bone and soft tissue sarcoma.
Front Oncol. 2024 Jun 21;14:1344643. doi: 10.3389/fonc.2024.1344643. eCollection 2024.
9
Clemastine and hyperthermia enhance sensitization of osteosarcoma cells for apoptosis.
Mol Cell Oncol. 2024 May 14;11(1):2351622. doi: 10.1080/23723556.2024.2351622. eCollection 2024.
10
Lipid Peroxidation-Related Redox Signaling in Osteosarcoma.
Int J Mol Sci. 2024 Apr 22;25(8):4559. doi: 10.3390/ijms25084559.
本文引用的文献
1
R1507, a fully human monoclonal antibody targeting IGF-1R, is effective alone and in combination with rapamycin in inhibiting growth of osteosarcoma xenografts.
Pediatr Blood Cancer. 2010 Jul 15;55(1):67-75. doi: 10.1002/pbc.22479.
2
Extracellular matrix: a gatekeeper in the transition from dormancy to metastatic growth.
Eur J Cancer. 2010 May;46(7):1181-8. doi: 10.1016/j.ejca.2010.02.027. Epub 2010 Mar 19.
3
How the NOTCH pathway contributes to the ability of osteosarcoma cells to metastasize.
Cancer Treat Res. 2009;152:479-96. doi: 10.1007/978-1-4419-0284-9_28.
4
Wnt inhibitory factor 1 decreases tumorigenesis and metastasis in osteosarcoma.
Mol Cancer Ther. 2010 Mar;9(3):731-41. doi: 10.1158/1535-7163.MCT-09-0147. Epub 2010 Mar 2.
5
Activation of signal transducer and activator of transcription 3 (Stat3) pathway in osteosarcoma cells and overexpression of phosphorylated-Stat3 correlates with poor prognosis.
J Orthop Res. 2010 Jul;28(7):971-8. doi: 10.1002/jor.21088.
6
Targeted therapies in bone sarcomas.
Curr Cancer Drug Targets. 2009 Nov;9(7):843-53. doi: 10.2174/156800909789760410.
7
Sorafenib blocks tumour growth, angiogenesis and metastatic potential in preclinical models of osteosarcoma through a mechanism potentially involving the inhibition of ERK1/2, MCL-1 and ezrin pathways.
Mol Cancer. 2009 Dec 10;8:118. doi: 10.1186/1476-4598-8-118.
8
The role of interferons in the treatment of osteosarcoma.
Pediatr Blood Cancer. 2010 Mar;54(3):350-4. doi: 10.1002/pbc.22136.
9
Inactive Wnt/beta-catenin pathway in conventional high-grade osteosarcoma.
J Pathol. 2010 Jan;220(1):24-33. doi: 10.1002/path.2628.
10
Src kinases as therapeutic targets for cancer.
Nat Rev Clin Oncol. 2009 Oct;6(10):587-95. doi: 10.1038/nrclinonc.2009.129.
Zotero 插件